Skip to main content
SP5007,691.76-0.69%DOW53,343.40-0.22%NASDAQ26,289.71-1.33%BTC$64,891.00+1.26%ETH$1,935.21+2.09%GOLD$4,498.50+1.76%OIL$84.24+0.21%
Smart Investors Daily
Sign InSign Up Free
RN

NASDAQ · RNAC

Cartesian Therapeutics, Inc.

Healthcare · Biotechnology

$9.20

Up+$0.02 (+0.22%)

Updated Aug 19, 2026, 12:21 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
222.59M
P/E ratio
-4.64
Dividend yield
0.00%
52-week range
$5.60 – $11.80
Volume
138.35K
Avg. volume
136.97K

Price performance

RNAC price history

1M range · 21 trading sessions · Daily adjusted prices

RNAC closed at $9.20 after 21 trading sessions, up 13.16% for the selected period.

Last close
$9.20
Period change
+13.16%
Period low
$7.42
Period high
$9.20
Daily close
View OHLC price history
RNAC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 18, 2026$9.06$9.6115$9.00$9.20138.35K
Aug 17, 2026$8.97$9.53$8.745$9.18108.7K
Aug 14, 2026$8.77$8.96$8.5035$8.8486.4K
Aug 13, 2026$8.76$8.89$8.70$8.7257.21K
Aug 12, 2026$8.59$8.86$8.47$8.67574.75K
Aug 11, 2026$8.82$8.82$8.43$8.58574.76K
Aug 10, 2026$8.79$8.885$8.64$8.7655.86K
Aug 7, 2026$8.88$8.95$8.615$8.8584.11K
Aug 6, 2026$8.48$8.87$8.4458$8.76105.58K
Aug 5, 2026$8.15$8.50$8.10$8.35113.23K
Aug 4, 2026$7.93$8.61$7.77$8.06297.96K
Aug 3, 2026$7.89$7.93$7.675$7.87111.95K
Jul 31, 2026$7.77$7.80$7.31$7.80140.25K
Jul 30, 2026$7.42$7.74$7.36$7.7398.71K
Jul 29, 2026$7.68$7.91$7.27$7.42168.82K
Jul 28, 2026$7.84$7.84$7.42$7.65106.23K
Jul 27, 2026$7.99$8.35$7.78$7.7979.05K
Jul 24, 2026$7.94$8.0297$7.66$7.88143.29K
Jul 23, 2026$7.99$8.26$7.60$7.92140.71K
Jul 22, 2026$8.07$8.3123$7.98$8.1386.54K
Jul 21, 2026$8.07$8.29$7.905$8.13151.83K

Latest RNAC news

The latest Smart Investors Daily articles mentioning RNAC.

Stock researchCompany · Overview

RNAC research

Overview

Company profile and research snapshot.

Company profile

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.67
Implied upside
—
Analysts
—
RNAC recent ratings
DateFirmRatingTarget
Aug 18, 2026WedbushOutperform—
Jun 10, 2026WedbushOutperform—
Jun 9, 2026NeedhamBuy—
Jun 9, 2026BTIGBuy—
May 27, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 14, 2026

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

The generalized myasthenia gravis market in 7MM is expected to show positive growth during the forecast period (2025–2034), mainly driven by the anticipated launch of emerging therapies such as Descartes-08 (Cartesian Therapeutics), FABHALTA (iptacopan) (Novartis), Claseprubart (DNTH103) (Dianthus Therapeutics), and others, and the increasing incidence of gMG.New York, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Pe

Yahoo · Jan 9, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FR

Yahoo · Jan 6, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By